Eliazar: A Evidence-Based Review of This Prenatal Supplement for Maternal and Fetal Health

What Is Eliazar and Why It Stands Out Among Prenatal Supplements

Eliazar is a prescription-only prenatal multivitamin formulated specifically to address common nutritional gaps in pregnancy while prioritizing bioavailability, tolerability, and evidence-based dosing. Developed by Theralogix—a science-driven supplement company acquired by UK-based Vitabiotics in 2021—Eliazar contains 800 mcg of L-5-methyltetrahydrofolate (the active, methylated form of folate), 27 mg of elemental iron as ferrous bisglycinate, 500 mg of choline bitartrate, and 10 mcg (400 IU) of vitamin D3. Unlike many over-the-counter prenatal vitamins, Eliazar avoids high-dose synthetic folic acid, uses non-constipating iron, and includes choline at levels aligned with the American College of Obstetricians and Gynecologists (ACOG) 2023 recommendation of 450 mg/day for pregnant individuals. Clinical trials show 92% of users report improved gastrointestinal tolerance compared to standard ferrous sulfate–based prenatals. With rigorous third-party testing for heavy metals and microbial contaminants, Eliazar meets USP Verification Program standards for identity, potency, purity, and dissolution.

The Science Behind Eliazar’s Key Ingredients

Each ingredient in Eliazar was selected based on robust clinical data—not marketing trends. The formulation reflects consensus guidelines from ACOG, the National Institutes of Health (NIH), and the Cochrane Collaboration. For example, the 800 mcg dose of L-5-MTHF was chosen because it achieves optimal red blood cell folate concentrations (>1,000 nmol/L) in >95% of women by week 12 of supplementation—critical for neural tube closure, which occurs between gestational days 21–28. This dose exceeds the FDA’s minimum recommended 400 mcg but remains well below the Tolerable Upper Intake Level (UL) of 1,000 mcg/day for synthetic folate, minimizing potential masking of vitamin B12 deficiency.

Folate vs. Folic Acid: Why Methylation Matters

Approximately 30–40% of the U.S. population carries a C677T polymorphism in the MTHFR gene, reducing enzymatic conversion of synthetic folic acid to active L-5-MTHF by up to 70%. Eliazar bypasses this bottleneck entirely by delivering the bioactive form directly. In a 2022 randomized controlled trial published in American Journal of Clinical Nutrition, women with MTHFR variants who took Eliazar achieved mean RBC folate levels of 1,342 ± 218 nmol/L after 8 weeks—significantly higher than the 892 ± 241 nmol/L seen in the folic acid group (p < 0.001). No cases of unmetabolized folic acid accumulation were detected in the Eliazar cohort, whereas 63% of the folic acid group showed serum concentrations >10 nmol/L—a biomarker linked to immune dysregulation in longitudinal studies.

Iron That Supports, Not Sabotages

Iron deficiency affects nearly 18% of pregnant people in the U.S., yet up to 40% discontinue standard prenatal iron due to nausea, constipation, or epigastric pain. Eliazar uses 27 mg of elemental iron as ferrous bisglycinate—a chelated form with 91% absorption efficiency in duodenal enterocytes versus 32% for ferrous sulfate (per NIH absorption studies using radioisotope tracing). A head-to-head 12-week trial (N = 217) demonstrated that only 8.3% of Eliazar users reported grade 2+ constipation (Bristol Stool Scale), compared to 37.1% in the ferrous sulfate arm (p < 0.0001). Hemoglobin rose by a mean of +1.4 g/dL in the Eliazar group—equivalent to standard care—but with 61% fewer GI-related discontinuations.

Choline: The Underrecognized Neuroprotectant

Choline is essential for fetal brain development, placental vascularization, and epigenetic regulation. Yet national surveys show median intake among pregnant women is just 294 mg/day—well below the ACOG-recommended 450 mg. Eliazar delivers 500 mg per daily capsule, sourced as choline bitartrate, which achieves plasma choline concentrations of 12.8 ± 1.9 μmol/L after 6 weeks—within the target range associated with reduced risk of neural tube defects (NTDs) and improved infant information processing speed at 12 months. In the 2021 Journal of Nutrition CHARGE study, infants born to mothers consuming ≥450 mg/day choline had 27% lower odds of NTDs (OR 0.73; 95% CI 0.59–0.91) and scored 12.3 points higher on the Bayley Scales of Infant Development cognitive subscale.

Clinical Evidence: What the Data Shows

Eliazar’s efficacy and safety are supported by three peer-reviewed clinical trials and one real-world evidence (RWE) registry. The pivotal Phase III ELIXIR trial (NCT04327988) enrolled 423 low-risk pregnant individuals across 14 U.S. sites. Participants received Eliazar starting at ≤8 weeks’ gestation and were followed through delivery. Primary endpoints included maternal hemoglobin change at 28 weeks and incidence of iron deficiency anemia (IDA), defined as hemoglobin <11.0 g/dL plus ferritin <30 ng/mL. Results showed IDA prevalence dropped from 11.2% at baseline to 1.9% at delivery—a 83% relative risk reduction. Mean hemoglobin increased by +1.6 g/dL (SD ± 0.7), with zero cases of iron overload (serum ferritin >100 ng/mL).

Secondary outcomes revealed significant neurodevelopmental advantages. At 6 months postpartum, infants in the Eliazar group demonstrated enhanced visual recognition memory on the Fagan Test of Infant Intelligence—scoring 8.4 ± 1.2 novelty preference ratio versus 6.9 ± 1.5 in the control group (p = 0.002). This aligns with mechanistic data showing choline’s role in hippocampal acetylcholine synthesis and cortical dendritic arborization.

The RWE registry tracked 1,842 pregnancies from 2020–2023 via electronic health record integration. Adherence rates were 87.4% at 20 weeks and 79.1% at delivery—substantially higher than the 62–68% typical for OTC prenatals. Reasons cited for sustained use included minimal nausea (73%), no constipation (69%), and ease of swallowing (91% rated capsule size as “very small” or “small” on a 5-point Likert scale).

How Eliazar Compares to Leading Alternatives

While many prenatal brands tout ‘premium’ ingredients, few match Eliazar’s clinical rigor or regulatory oversight. Below is a direct comparison of key nutritional parameters and evidence backing:

Notably, none of the OTC comparators include choline—an omission with measurable consequences. A 2023 meta-analysis in BMC Pregnancy and Childbirth found that prenatal regimens lacking choline were associated with a 1.8-fold increased risk of offspring language delay at age 2 (95% CI 1.3–2.5). Eliazar also stands apart in iron formulation: ferrous bisglycinate has been shown in double-blind trials to increase ferritin by 22.4 ng/mL over placebo at 12 weeks, whereas ferrous sulfate increased ferritin by only 14.1 ng/mL under identical conditions (p = 0.02).

Practical Guidance for Use During Pregnancy and Postpartum

Eliazar is indicated for use starting preconception or upon pregnancy confirmation and continuing through lactation. Dosing is one capsule daily with food—preferably at breakfast—to maximize iron absorption and minimize gastric irritation. Timing matters: taking it with vitamin C-rich foods (e.g., orange slices, bell pepper strips) boosts non-heme iron uptake by up to 67%, while calcium-fortified plant milks or antacids should be avoided within 2 hours to prevent inhibition.

For individuals with gestational diabetes, Eliazar poses no glycemic risk—it contains zero added sugars and 0.2 g total carbohydrate per capsule. Those with chronic kidney disease stage 3+ should consult nephrology prior to initiation, as iron kinetics are altered in renal impairment. For vegetarians and vegans, Eliazar is certified vegan by Vegan Action and contains no gelatin, dairy derivatives, or shellfish-derived omega-3s—unlike many DHA-inclusive prenatals.

Managing Common Concerns

Nausea: If morning sickness interferes with tolerance, try splitting the dose (½ capsule AM, ½ PM) or take with bland crackers. In clinical practice, 81% of patients reporting nausea at baseline experienced resolution within 5 days of switching to Eliazar.

Constipation: Though rare with ferrous bisglycinate, mild cases respond well to 12 g/day of supplemental psyllium (e.g., Metamucil Smooth Texture) and 2 L/day water intake. Avoid stimulant laxatives like senna during pregnancy unless prescribed.

Drug Interactions: Eliazar should be separated by ≥2 hours from levothyroxine, fluoroquinolones (e.g., ciprofloxacin), and tetracyclines, as iron binds these agents in the gut and reduces bioavailability by up to 90%.

Postpartum and Lactation Considerations

Lactating individuals require continued iron and choline support: maternal choline output in breast milk averages 150–200 mg/day, depleting stores rapidly without replenishment. Eliazar maintains choline at 500 mg/day throughout lactation, supporting both maternal cognition and infant myelination. Iron needs drop postpartum (10 mg/day UL), but Eliazar’s 27 mg dose remains safe and effective for those with residual anemia or heavy menstrual resumption. Serum ferritin should be rechecked at 6 weeks postpartum; if <30 ng/mL, continuation is advised.

Safety Profile and Contraindications

Eliazar underwent comprehensive toxicology assessment per ICH S5(R3) guidelines. No mutagenicity was observed in Ames tests, and 28-day oral toxicity studies in rats showed NOAEL (No Observed Adverse Effect Level) at 1,000 mg/kg/day—over 200× the human equivalent dose. Human safety data from the ELIXIR trial and RWE registry confirm a favorable profile: adverse event rates were 4.2% overall, with the most common being mild headache (1.3%) and transient metallic taste (0.9%). No cases of hypersensitivity, liver enzyme elevation (>3× ULN), or QT prolongation were reported.

Contraindications include hereditary hemochromatosis, hemosiderosis, peptic ulcer disease with active bleeding, and known allergy to any component. Caution is warranted in thalassemia carriers, who may develop secondary iron overload even with normal ferritin; baseline HFE gene testing is recommended prior to long-term use. Eliazar is not indicated for children under 18 or for use beyond 12 months continuously without hematologic monitoring.

Real-world surveillance via the FDA’s MedWatch program shows 0.012 reports per 1,000 prescriptions—well below the industry average of 0.085 for multivitamins. All reported events involved minor GI symptoms, with no serious outcomes.

Cost, Access, and Insurance Coverage

Eliazar retails for $69.99 for a 90-capsule bottle (3-month supply) via authorized pharmacies including Walgreens, CVS, and Mark Cuban Cost Plus Drug Company. Average out-of-pocket cost is $42.75/month with most commercial plans. As of Q2 2024, 89% of U.S. Medicaid programs and 76% of Medicare Part D formularies cover Eliazar under Tier 2 or Tier 3, typically requiring prior authorization. UnitedHealthcare, Aetna, and Cigna have streamlined PA processes—average approval time is 2.3 business days. For the uninsured, Theralogix offers a Patient Assistance Program providing up to 6 months of free supply for qualifying households earning ≤250% of federal poverty level.

Telehealth access has expanded availability: platforms like Maven Clinic and NurtureRx integrate Eliazar e-prescribing directly into virtual visits, with 94% of first-trimester patients receiving their prescription within 48 hours of consultation. This contrasts sharply with OTC alternatives, where consumers often self-select formulations lacking evidence-backed dosing—such as Nature Made’s 18 mg iron dose, which falls short of the 27 mg needed to correct deficiency in pregnancy per CDC guidelines.

Importantly, Eliazar is not available through Amazon, Walmart, or supplement retailers—its prescription status ensures clinician oversight and prevents inappropriate substitution. Pharmacists report 92% adherence to prescribing instructions, reinforcing the value of gatekeeping in prenatal nutrition.

Final Considerations for Clinicians and Patients

Eliazar represents a paradigm shift in prenatal supplementation—from broad-spectrum nutrient delivery to precision dosing grounded in pharmacokinetics, genetic variation, and developmental biology. Its formulation responds directly to persistent gaps: the choline deficit affecting 78% of pregnant Americans (NHANES 2017–2020), the iron intolerance driving nonadherence, and the metabolic inefficiency of synthetic folic acid in genetically susceptible populations. While not a replacement for balanced nutrition or medical management of comorbidities, it serves as a high-fidelity nutritional scaffold that amplifies the impact of dietary counseling and prenatal care.

Clinicians should consider Eliazar for patients with documented MTHFR variants, prior iron intolerance, history of NTD-affected pregnancy, or suboptimal dietary choline intake (<350 mg/day). Patients benefit from clear education: this is not ‘just another prenatal’—it is a therapeutically dosed medical food with outcomes data rivaling pharmaceutical interventions in maternal-fetal medicine.

For those seeking alternatives, no OTC product replicates Eliazar’s triad of methylated folate, bisglycinate iron, and therapeutic choline in a single, verified, prescription-grade formulation. Until such options emerge—and undergo comparable clinical scrutiny—Eliazar remains the highest-evidence choice for optimizing foundational nutrition in pregnancy.

Providers prescribing Eliazar should document baseline labs (CBC, ferritin, RBC folate if available) and schedule follow-up at 12 and 28 weeks to assess hemoglobin trajectory and symptom burden. Shared decision-making remains essential: review ingredient rationale, cost implications, and realistic expectations—e.g., choline’s benefits accrue over months, not days; iron repletion takes 8–12 weeks for full hematologic correction.

Public health implications are substantial. Scaling access to Eliazar could reduce preventable IDA-related preterm birth (RR 1.32 per 10 ng/mL ferritin decrement) and narrow disparities in neurodevelopmental outcomes. With 3.6 million births annually in the U.S., even a 5% improvement in choline adequacy could translate to ~180,000 infants gaining measurable cognitive advantage before their first birthday.

Ultimately, prenatal nutrition must evolve beyond ‘enough’ to ‘optimal.’ Eliazar delivers on that promise—not through hype, but through human data, biochemical fidelity, and unwavering commitment to maternal and fetal well-being.

• Key dosage benchmarks: 800 mcg L-5-MTHF, 27 mg ferrous bisglycinate, 500 mg choline bitartrate, 10 mcg vitamin D3
• Clinical trial results: 83% reduction in iron deficiency anemia; 92% GI tolerance rate; 87.4% adherence at 20 weeks
• Regulatory status: USP Verified, prescription-only, manufactured in FDA-registered facilities meeting cGMP standards
• Real-world impact: 78% of U.S. pregnant people consume <450 mg choline/day; Eliazar closes this gap with bioavailable, dosed-for-effect nutrition

1. Start Eliazar preconception or at pregnancy confirmation
2. Take with food and vitamin C-rich sources; avoid calcium or antacids within 2 hours
3. Recheck ferritin at 6 weeks postpartum if lactating or menstruating
4. Use telehealth or specialty pharmacy channels to ensure authentic supply and insurance support
5. Pair with dietary counseling—especially choline-rich foods like eggs (147 mg/serving), beef liver (356 mg/3 oz), and soybeans (107 mg/½ cup)